Gallmeier W M, Bruntsch U
5. Medizinische Klinik und Institut für Medizinische Onkologie und Hämatologie, Klinikum der Stadt Nürnberg.
Onkologie. 1987 Aug;10(4):226-31. doi: 10.1159/000216410.
In oncology phase-II studies are planned for testing antitumor activity in a series of malignant tumors. Most important is the development of drugs from entirely new classes of chemicals, fermentation products etc. Clinical research with analogues of known cytotoxic drugs aims at broader spectra of activity and at decreased toxicity in an attempt to avoid, for example, the cardiac toxicity of the anthracyclines or the renal and gastrointestinal toxicities of cis-platinum.
在肿瘤学领域，二期研究旨在测试一系列恶性肿瘤中的抗肿瘤活性。最重要的是开发全新化学类别、发酵产物等的药物。对已知细胞毒性药物类似物的临床研究旨在获得更广泛的活性谱并降低毒性，例如试图避免蒽环类药物的心脏毒性或顺铂的肾脏和胃肠道毒性。
